

## Appendix A. Key Questions and PICOTS

### KEY QUESTIONS

1) What is the comparative effectiveness of high flow nasal oxygen versus noninvasive positive pressure ventilation (CPAP, BiPAP®) or conventional oxygen for hospitalized patients?

1a) Does comparative effectiveness of high flow nasal oxygen vary by patient characteristics, disease/diagnosis characteristics, protocol/device settings, or location of administration?

2) What are the harms of high flow nasal oxygen versus noninvasive positive pressure ventilation (CPAP, BiPAP®), invasive mechanical ventilation, or conventional oxygen for hospitalized patients?

2a) Do harms vary by patient characteristics, disease/diagnosis, protocol/device settings, or location of administration?

PICOTS	
<b>Population:</b>	Hospitalized adult patients with acute respiratory failure (ARF). ARF defined as SpO <sub>2</sub> <90%, PaO <sub>2</sub> :FiO <sub>2</sub> ratio ≤300, PaO <sub>2</sub> ≤60 mmHg, or PaCO <sub>2</sub> ≥45 mmHg
<b>Intervention:</b>	High flow nasal oxygen (humidified, ≥20 l/min)
<b>Comparators:</b>	Noninvasive positive pressure ventilation (CPAP, BiPAP®) or conventional oxygen (e.g., simple, Venturi, or nonrebreather oxygen masks)
<b>Outcomes:</b>	<p><b>Patient-centered Outcomes:</b> all-cause mortality (in-hospital and 90 day), intubation/reintubation (days of intubation), hospital length of stay, ICU admissions/transfers (ICU days), patient comfort, hospital readmissions (30 day) (e.g., all-cause, pneumonia), functional independence at discharge (e.g., scale scores, measures of independence/activities of daily living), discharge disposition</p> <p><b>Intermediate Outcomes:</b> respiratory rate, PaO<sub>2</sub>/FiO<sub>2</sub> ratio, SpO<sub>2</sub>, pH, PaO<sub>2</sub>, PaCO<sub>2</sub>, treatment escalation, device intolerance</p> <p><b>Cost/resource utilization</b></p> <p><b>Harms:</b> skin breakdown or pressure ulcers, gastric dysfunction, hospital-acquired pneumonia, compromised nutrition (enteral or parenteral nutrition), delirium, barotrauma</p>
<b>Timing:</b>	Hospitalization for ARF or development of ARF while hospitalized; immediate post-extubation; post-surgery. Exclude pre-intubation/pre-oxygenation and HFNO oxygenation support during intubation
<b>Setting:</b>	Hospital (including ICU, step down units, hospital wards), emergency department
<b>Study Design:</b>	Randomized controlled trials, including crossover RCTs and cluster RCTs
<b>Subgroups:</b>	<p>Patient characteristics: age, race, gender</p> <p>Disease/diagnosis (e.g. COPD, cardiogenic pulmonary edema, immunosuppressed, post-extubation, post-surgery; hypoxic, hypercapnic, or mixed [hypoxic or hypercapnic] respiratory failure)</p> <p>Protocol/device settings (e.g., flow rate ≤30 vs. &gt;30 L/min; treatment duration &lt;6 vs. ≥6 hours)</p>

BiPAP=Bilevel Positive Airway Pressure; CPAP=continuous positive airway pressure; ICU=intensive care unit; COPD= chronic obstructive pulmonary disease

### LITERATURE SEARCH

RCTs: We will search MEDLINE, Embase, CINAHL, and Cochrane Library from 2000 to August 2019 Clinicaltrials.gov for recently completed and/or on-going trials

Reference lists from relevant systematic reviews for references missed by our database searches

## Analytic Framework

